Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study
Clinical Infectious Diseases·
- DOI
- 10.1093/cid/ciae584
- PMID
- 39607747
- PMCID
- PMC13016773
- OpenAlex
- W4404814594
- Study type
- Journal article
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
These findings support current clinical guideline recommendations to initiate antiviral therapy as soon as possible in hospitalized influenza patients. Early oseltamivir treatment was associated with meaningful reductions in severe complications and death among hospitalized adults.
Structured evidence summary
Research question
The study examined whether initiating oseltamivir on the day of hospital admission reduces disease severity and adverse outcomes in adults hospitalized with laboratory-confirmed influenza.
Study design
This was a multicenter prospective observational study conducted through a US sentinel surveillance network at 24 hospitals between October 2022 and July 2023. The analysis used multivariable regression models to compare outcomes between patients who started oseltamivir on admission day versus those treated later or not at all, adjusting for baseline severity, demographics, site, and vaccination status.
Population and setting
The study enrolled 840 adults aged 18 years and older hospitalized with laboratory-confirmed influenza A across 24 US hospitals. Among these, 415 patients (49%) received oseltamivir on the day of admission and 425 (51%) received it later or not at all.
Main findings
Patients who received oseltamivir on admission day had lower peak pulmonary disease severity (adjusted OR 0.60, 95% CI 0.49-0.72), reduced odds of ICU admission (adjusted OR 0.24, 95% CI 0.13-0.47), lower odds of acute kidney replacement therapy or vasopressor use (adjusted OR 0.40, 95% CI 0.22-0.67), and lower in-hospital mortality (adjusted OR 0.36, 95% CI 0.18-0.72) compared to those treated later or not treated.
Public-health relevance
These findings support current clinical guideline recommendations to initiate antiviral therapy as soon as possible in hospitalized influenza patients. Early oseltamivir treatment was associated with meaningful reductions in severe complications and death among hospitalized adults.
Important limitations
As an observational study, unmeasured confounding may affect the association between treatment timing and outcomes despite statistical adjustment. The summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation of study limitations, potential biases, and generalizability.
GIDS interpretation
This peer-reviewed journal article was classified under influenza surveillance and treatment topics for the United States. It provides evidence on antiviral effectiveness in hospitalized patients during the 2022-2023 influenza season but does not represent a surveillance signal or trend analysis.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.